Phase II Study of Cisplatin plus Cetuximab in Advanced, Recurrent, and Previously Treated Cancers of the Cervix and Evaluation of Epidermal Growth Factor Receptor Immunohistochemical Expression: A Gynecologic Oncology Group Study

BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of cetuximab (C225), an antibody that inhibits epidermal growth factor receptor (EGFR) activity, with cisplatin and to explore associations between EGFR protein expression with patient demographics or clinical outcome. MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Farley, John, Sill, Michael W., Birrer, Michael, Walker, Joan, Schilder, Russell J., Thigpen, J. Tate, Coleman, Robert L, Miller, Brigitte E., Rose, Peter G., Lankes, Heather A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3081894/
https://ncbi.nlm.nih.gov/pubmed/21329967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.01.030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados